James Hinrichs - Orthofix Medical Independent Director
| OFIX Stock | USD 13.10 0.46 3.39% |
Director
Mr. James F. Hinrichs is Independent Director of the Company., since April 2014. Since April 2018, he has served as Chief Financial Officer of Cibus, a privatelyheld agricultural biotech company. From April 2015 to October 2017, he served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company, prior to its sale to Abbott Labs. From December 2010 through March 2015, he served as Chief Financial Officer of CareFusion Corporationrationration, a publicly traded medical technology company, prior to its sale to Becton Dickinson. He previously served as CareFusions Senior Vice President, Global Customer Support, from January 2010 to December 2010, and as its Senior Vice President, Controller, from January 2009 to January 2010. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked since 2004 at Cardinal Health in various positions including Executive Vice President and Corporationrationrate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following over a decade of finance and marketing roles at Merck Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University. since 2014.
| Age | 50 |
| Tenure | 10 years |
| Address | 3451 Plano Parkway, Lewisville, TX, United States, 75056 |
| Phone | 214 937 2000 |
| Web | https://www.orthofix.com |
Orthofix Medical Management Efficiency
The company has return on total asset (ROA) of (0.063) % which means that it has lost $0.063 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3236) %, meaning that it created substantial loss on money invested by shareholders. Orthofix Medical's management efficiency ratios could be used to measure how well Orthofix Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.23 in 2024. Return On Capital Employed is likely to rise to -0.18 in 2024. At this time, Orthofix Medical's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 530.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 20.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jo Golden | CONMED | 69 | |
| Hugh Morrison | LivaNova PLC | 70 | |
| Roxanne Coady | Paragon 28 | 64 | |
| Alvin Jeffers | Integer Holdings Corp | 47 | |
| Susan Harnett | Paragon 28 | 57 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Stephen ONeil | Alphatec Holdings | 82 | |
| Marc Stapley | Glaukos Corp | 50 | |
| James Tobin | Globus Medical | 75 | |
| Austin Adams | Paragon 28 | 71 | |
| Bryan Hughes | Orthopediatrics Corp | 40 | |
| Samuel Riccitelli | Orthopediatrics Corp | 59 | |
| Martha Aronson | CONMED | 53 | |
| Dirk Kuyper | CONMED | 61 | |
| John Foster | Alphatec Holdings | 71 | |
| Arthur Rosenthal | LivaNova PLC | 70 | |
| Stephen Fesik | Bruker | 61 | |
| George Philip | Paragon 28 | 67 | |
| Alfred Novak | LivaNova PLC | 70 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Daniel Lemaitre | Globus Medical | 66 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.063 |
Orthofix Medical Leadership Team
Elected by the shareholders, the Orthofix Medical's board of directors comprises two types of representatives: Orthofix Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orthofix. The board's role is to monitor Orthofix Medical's management team and ensure that shareholders' interests are well served. Orthofix Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orthofix Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Paolucci, Independent Director | ||
| Rice Doug, CFO | ||
| Doug Rice, Interim CFO, Chief Accounting Officer | ||
| Lucas Vitale, Chief Officer | ||
| Frank Vizesi, Chief Officer | ||
| Julie Andrews, Chief Officer | ||
| Roberto Donadello, Senior Operations | ||
| Jeffrey Schumm, Chief Admin. Officer, General Counsel and Corporate Secretary | ||
| Mark Quick, Sr Relations | ||
| Tyler Lipschultz, President Biologics | ||
| Dan Yarbrough, Vice Relations | ||
| James Hinrichs, Independent Director | ||
| BA Chemistry, Chief Officer | ||
| Kimberley Elting, President Orthopedics | ||
| Bradley Mason, CEO and President and Director | ||
| Robert Goodwin, President - Biologics | ||
| Alexis Lukianov, Independent Director | ||
| Raymond Fujikawa, President - Spine Fixation | ||
| Davide Bianchi, President of Global Extremity Fixation | ||
| Anthony Martin, Independent Director | ||
| Ehab Esmail, Regulatory Quality | ||
| Guy Jordan, Independent Director | ||
| Suzanne Armstrong, Chief Officer | ||
| Bradley Niemann, President - BioStim | ||
| Douglas Rice, CFO Officer | ||
| Jon Serbousek, President - Global Spine Business | ||
| Jill Mason, Interim Counsel | ||
| Michael Finegan, Chief Strategy Officer | ||
| Ronald Matricaria, Independent Chairman of the Board | ||
| Maria Sainz, Independent Director | ||
| Lilly Marks, Director | ||
| Kevin Kenny, President Business | ||
| John Sicard, Independent Director | ||
| Luke Faulstick, Director | ||
| Massimo Calafiore, CEO President |
Orthofix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orthofix Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.063 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 608.33 M | ||||
| Shares Outstanding | 37.41 M | ||||
| Shares Owned By Insiders | 3.52 % | ||||
| Shares Owned By Institutions | 97.81 % | ||||
| Number Of Shares Shorted | 3.78 M | ||||
| Price To Earning | 338.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Orthofix Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Orthofix Medical's short interest history, or implied volatility extrapolated from Orthofix Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orthofix Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Orthofix Stock please use our How to Invest in Orthofix Medical guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Orthofix Stock analysis
When running Orthofix Medical's price analysis, check to measure Orthofix Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orthofix Medical is operating at the current time. Most of Orthofix Medical's value examination focuses on studying past and present price action to predict the probability of Orthofix Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orthofix Medical's price. Additionally, you may evaluate how the addition of Orthofix Medical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Orthofix Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orthofix Medical. If investors know Orthofix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orthofix Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.12) | Revenue Per Share 20.328 | Quarterly Revenue Growth 0.64 | Return On Assets (0.06) | Return On Equity (0.32) |
The market value of Orthofix Medical is measured differently than its book value, which is the value of Orthofix that is recorded on the company's balance sheet. Investors also form their own opinion of Orthofix Medical's value that differs from its market value or its book value, called intrinsic value, which is Orthofix Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orthofix Medical's market value can be influenced by many factors that don't directly affect Orthofix Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orthofix Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orthofix Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orthofix Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.